Carbonic anhydrase inhibition by 1-aroyl-3-(4-aminosulfonylphenyl)thioureas

References

• Breton S. The cellular physiology of carbonic anhydrases. J Pancrease 2001;2:159–64
   PubMedGoogle Scholar
• Imtaiyaz Hassan M, Shajee B, Waheed A, et al. Structure, function and applications of carbonic anhydrase isozymes. Bioorg Med Chem 2013;21:1570–82
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146–89
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin Ther Pat 2000;10:575–600
   Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases as drug targets -- an overview. Curr Top Med Chem 2007;7:825–33
   PubMed Web of Science ®Google Scholar
• De Simone G, Supuran CT. Antiobesity carbonic anhydrase inhibitors. Curr Top Med Chem 2007;7:879–84
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A. Carbonic anhydrases as targets for medicinal chemistry. Bioorg Med Chem 2007;15:4336–50
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004;19:199–229
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Vullo D, Casini A, et al. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with polyfluorinated aromatic/heterocyclic sulfonamides. J Enzyme Inhib Med Chem 2005;20:211–17
   PubMed Web of Science ®Google Scholar
• Poulsen SA. Carbonic anhydrase inhibition as a cancer therapy: a review of patent literature, 2007–2009. Expert Opin Ther Pat 2010;20:795–806
   PubMed Web of Science ®Google Scholar
• Said HM, Hagemann C, Carta F, et al. Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma. Bioorg Med Chem 2013;21:3949–57
   PubMed Web of Science ®Google Scholar
• Thiry A, Dogné JM, Masereel B, Supuran CT. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 2006;27:566–73
   PubMed Web of Science ®Google Scholar
• Winum JY, Scozzafava A, Montero JL, Supuran CT. Inhibition of carbonic anhydrase IX: a new strategy against cancer. Anticancer Agents Med Chem 2009;9:693–702
   PubMed Web of Science ®Google Scholar
• Guler OO, De Simone G, Supuran CT. Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII. Curr Med Chem 2010;17:1516–26
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Zatovicova M, Pastorek J. Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des 2008;14:685–98
   PubMed Web of Science ®Google Scholar
• Winum JY, Rami M, Scozzafava A, et al. Carbonic anhydrase IX: a new druggable target for the design of antitumor agents. Med Res Rev 2008;28:445–63
   PubMed Web of Science ®Google Scholar
• Guler OO, De Simone G, Supuran CT. Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII. Curr Med Chem 2010;17:1516–26
   PubMed Web of Science ®Google Scholar
• De Simone G, Supuran CT. Carbonic anhydrase IX: biochemical and crystallographic characterization of a novel antitumor target. Biochim Biophys Acta 2010;1804:404–9
   PubMed Web of Science ®Google Scholar
• Gieling RG, Williams KJ. Carbonic anhydrase IX as a target for metastatic disease. Bioorg Med Chem 2013;21:1470–6
   PubMed Web of Science ®Google Scholar
• Said HM, Staab A, Hagemann C, et al. Distinct patterns of hypoxic expression of carbonic anhydrase IX (CA IX) in human malignant glioma cell lines. J Neurooncol 2007;81:27–38
   PubMed Web of Science ®Google Scholar
• Takacova M, Holotnakova T, Barathova M, et al. Src induces expression of carbonic anhydrase IX via hypoxia-inducible factor 1. Oncol Rep 2010;23:869–74
   PubMed Web of Science ®Google Scholar
• Kivelä AJ, Knuuttila A, Räsänen J, et al. Carbonic anhydrase IX in malignant pleural mesotheliomas: a potential target for anti-cancer therapy. Bioorg Med Chem 2013;21:1483–8
   PubMed Web of Science ®Google Scholar
• Monti SM, Supuran CT, De Simone G. Anticancer carbonic anhydrase inhibitors: a patent review (2008–2013). Expert Opin Ther Pat 2013;23:737–49
   PubMed Web of Science ®Google Scholar
• Winum JY, Temperini C, El Cheikh K, et al. Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem 2006;49:7024–31
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004;19:199–229
   PubMed Web of Science ®Google Scholar
• Supuran CT, Vullo D, Manole G, et al. Designing of novel carbonic anhydrase inhibitors and activators. Curr Med Chem Cardiovasc Hematol Agents 2004;2:49–68
   PubMedGoogle Scholar
• Saeed A, Zaib S, Pervez A, et al. Synthesis, molecular docking studies, and in vitro screening of sulfanilamide-thiourea hybrids as antimicrobial and urease inhibitors. Med Chem Res 2013;22:3653–62
   Web of Science ®Google Scholar
• Pocker Y, Stone JT. The catalytic versatility of erythrocyte carbonic anhydrase. 3. Kinetic studies of the enzyme-catalyzed hydrolysis of p-nitrophenyl acetate. Biochemistry 1967;6:668–78
   PubMed Web of Science ®Google Scholar
• Ul-Haq Z, Usmani S, Mahmood U, et al. In-silico analysis of chromone containing sulfonamide derivatives as human carbonic anhydrase inhibitors. Med Chem 2013;9:608–16
   PubMed Web of Science ®Google Scholar
• ACD/ChemSketch, version 12.01, Advanced Chemistry Development, Inc., Toronto, ON, Canada; 2013. Available from: www.acdlabs.com
   Google Scholar
• Wang J, Wang W, Kollman PA, Case DA. Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model 2006;25:247–60
   PubMed Web of Science ®Google Scholar
• Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera – a visualization system for exploratory research and analysis. J Comput Chem 2004;25:1605–12
   PubMed Web of Science ®Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J Comput Chem 2009;16:2785–91
   Web of Science ®Google Scholar
• Accelrys Software Inc., Discovery Studio Modeling Environment, Release 4.0, San Diego (CA): Accelrys Software Inc.; 2013
   Google Scholar
• Chen VB, Arendall WB 3rd, Headd JJ, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr 2010;D66:12–21
   PubMed Web of Science ®Google Scholar
• Davis IW, Leaver-Fay A, Chen VB, et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 2007;35:W375–83
   PubMed Web of Science ®Google Scholar
• Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comp Chem 1998;19:1639–62
   Web of Science ®Google Scholar
• Vullo D, Franchi M, Gallori E, et al. Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J Med Chem 2004;47:1272–9
   PubMed Web of Science ®Google Scholar
• Ricci CG, Netz PA. Docking studies on DNA-ligand interactions: building and application of a protocol to identify the binding mode. J Chem Inf Model 2009;49:1925–35
   PubMed Web of Science ®Google Scholar
• Cosconati S, Forli S, Perryman AL, et al. Virtual screening with AutoDock: theory and practice. Expert Opin Drug Discov 2010;5:597–607
   PubMed Web of Science ®Google Scholar
• Supuran CT, Vullo D, Manole G, et al. Designing of novel carbonic anhydrase inhibitors and activators. Curr Med Chem Cardiovasc Hematol Agents 2004;2:49–68
   PubMedGoogle Scholar
• Supuran CT, Scozzafava A. Carbonic anhydrases as targets for medicinal chemistry. Bioorg Med Chem 2007;15:4336–50
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3–25
   Web of Science ®Google Scholar
• Leeson P. Drug discovery: chemical beauty contest. Nature 2012;481:455–6
   PubMed Web of Science ®Google Scholar
• Zakeri-Milani P, Tajerzadeh H, Islambolchilar Z, et al. The relation between molecular properties of drugs and their transport across the intestinal membrane. DARU 2006;14:164–71
   Google Scholar
• Asokkumar K, Prathyusha LT, Umamaheshwari M, et al. Design, admet and docking studies on some novel chalcone derivatives as soluble epoxide hydrolase enzyme inhibitors. J Chil Chem Soc 2012;57:1442–6
   Web of Science ®Google Scholar
• Clark DE, Pickett SD. Computational methods for the prediction of drug likeness. Drug Discov Today 2000;5:49–58
   PubMed Web of Science ®Google Scholar